09 April 2024
09 April 2024
J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma.
The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.
The companies will form Petalion Therapeutics, which will initially focus on creating dendrimer-drug conjugate therapies.
In the second part of this series, F. Randy Vogenberg talks about how planning early can positively impact insurance coverage for new therapies, especially in the case of orphan drugs.
In an interview with Pharmaceutical Technology, Pluri’s CEO discussed its recent launch as a CDMO, as well as its cell therapy pipeline.
Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.
Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.
Lipocine has been granted a patent for bioavailable solid state esters of (17-ß)-Hydroxy-4-Androsten-3-one for pharmaceutical use.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
